Rosetta Genomics Could Debut Colon Cancer Screen in US This Year, Shifts Focus from Dxs | GenomeWeb

This story has been updated to include comments by Rosetta management and the company's fourth-quarter financial results.

Rosetta Genomics this week said it could begin selling its blood-based microRNA screening diagnostic for colon cancer in the US before the end of the year, rather than in 2010 as previously expected.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Nature this week: genomic analysis of 200 bird species, and more.

The Australian High Court rules that isolated genetic material cannot be patented.

The startup incubator Y Combinator is launching a nonprofit research lab.

In Genome Research this week: vervet genome, tandem repeats affect gene expression in great apes, and more.